Given that pCR rate for women with HR-/ERBB2+ disease was also highest of all breast cancer subtypes, as shown in this and other studies,30 disparate response to similar treatment plans suggested the existence of underexplored biological differences. Here, ERBB2 is linked to breast carcinoma.